Jennifer Crombie1, Philippe Armand2. 1. Dana-Farber Cancer Institute, Boston, MA, USA. jennifer_crombie@dfci.harvard.edu. 2. Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract
PURPOSE OF THE REVIEW: Lymphomas represent clinically and molecularly heterogeneous diseases with variable presentations, treatment algorithms, and outcomes. As treatment options continue to expand, more sophisticated prognostic and predictive biomarkers are needed to guide personalized treatment approaches. RECENT FINDINGS: Liquid biopsies, in which the sequencing of circulating tumor DNA (ctDNA) in peripheral blood serves as a surrogate for a tumor biopsy, are now being studied across cancer subtypes, including in lymphoid malignancies. Recent studies have demonstrated the potential of these techniques to improve prognostication and guide individualized treatment strategies, providing a significant advance in the field of precision medicine. In this review, we describe the sequencing platforms currently available for analysis of ctDNA in lymphoma and their potential applications in clinical practice, which seem poised to refine treatment paradigms across lymphoma subtypes.
PURPOSE OF THE REVIEW: Lymphomas represent clinically and molecularly heterogeneous diseases with variable presentations, treatment algorithms, and outcomes. As treatment options continue to expand, more sophisticated prognostic and predictive biomarkers are needed to guide personalized treatment approaches. RECENT FINDINGS: Liquid biopsies, in which the sequencing of circulating tumor DNA (ctDNA) in peripheral blood serves as a surrogate for a tumor biopsy, are now being studied across cancer subtypes, including in lymphoid malignancies. Recent studies have demonstrated the potential of these techniques to improve prognostication and guide individualized treatment strategies, providing a significant advance in the field of precision medicine. In this review, we describe the sequencing platforms currently available for analysis of ctDNA in lymphoma and their potential applications in clinical practice, which seem poised to refine treatment paradigms across lymphoma subtypes.
Authors: Christiane Pott; Eva Hoster; Marie-Helene Delfau-Larue; Kheira Beldjord; Sebastian Böttcher; Vahid Asnafi; Anne Plonquet; Reiner Siebert; Evelyne Callet-Bauchu; Niels Andersen; Jacques J M van Dongen; Wolfram Klapper; Françoise Berger; Vincent Ribrag; Achiel L van Hoof; Marek Trneny; Jan Walewski; Peter Dreger; Michael Unterhalt; Wolfgang Hiddemann; Michael Kneba; Hanneke C Kluin-Nelemans; Olivier Hermine; Elizabeth Macintyre; Martin Dreyling Journal: Blood Date: 2009-12-23 Impact factor: 22.113
Authors: Peter Vandenberghe; Iwona Wlodarska; Thomas Tousseyn; Luc Dehaspe; Daan Dierickx; Magali Verheecke; Anne Uyttebroeck; Oliver Bechter; Michel Delforge; Vincent Vandecaveye; Nathalie Brison; Gregor E G Verhoef; Eric Legius; Frederic Amant; Joris R Vermeesch Journal: Lancet Haematol Date: 2015-01-20 Impact factor: 18.959
Authors: Francesc Bosch; Ana Ferrer; Neus Villamor; Marcos González; Javier Briones; Eva González-Barca; Eugenia Abella; Santiago Gardella; Lourdes Escoda; Elena Pérez-Ceballos; Antoni Asensi; Ma José Sayas; Llorenç Font; Albert Altés; Ana Muntañola; Paola Bertazzoni; María Rozman; Marta Aymerich; Eva Giné; Emili Montserrat Journal: Clin Cancer Res Date: 2008-01-01 Impact factor: 12.531
Authors: Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Atanas Kamburov; Robert A Redd; Mike S Lawrence; Margaretha G M Roemer; Amy J Li; Marita Ziepert; Annette M Staiger; Jeremiah A Wala; Matthew D Ducar; Ignaty Leshchiner; Ester Rheinbay; Amaro Taylor-Weiner; Caroline A Coughlin; Julian M Hess; Chandra S Pedamallu; Dimitri Livitz; Daniel Rosebrock; Mara Rosenberg; Adam A Tracy; Heike Horn; Paul van Hummelen; Andrew L Feldman; Brian K Link; Anne J Novak; James R Cerhan; Thomas M Habermann; Reiner Siebert; Andreas Rosenwald; Aaron R Thorner; Matthew L Meyerson; Todd R Golub; Rameen Beroukhim; Gerald G Wulf; German Ott; Scott J Rodig; Stefano Monti; Donna S Neuberg; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper; Gad Getz; Margaret A Shipp Journal: Nat Med Date: 2018-04-30 Impact factor: 53.440
Authors: P Abrisqueta; D W Scott; G W Slack; C Steidl; A Mottok; R D Gascoyne; J M Connors; L H Sehn; K J Savage; A S Gerrie; D Villa Journal: Ann Oncol Date: 2017-10-01 Impact factor: 32.976